252331-63-8

Basic information

• Product Name: 1-(6-broMo-3,4-dihydro-2(1H)-isoquinolinyl)-2,2,2-trifluoro-Ethanone
• Synonyms: 1-(6-broMo-3,4-dihydro-2(1H)-isoquinolinyl)-2,2,2-trifluoro-Ethanone;6-Bromo-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline
• CAS NO: 252331-63-8
• Molecular Formula: C₁₁H₉BrF₃NO
• Molecular Weight: 308.0944696
• EINECS: -0
• Mol File: 252331-63-8.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 392.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.611±0.06 g/cm3(Predicted)
• PKA: -1.92±0.20(Predicted)
• CAS DataBase Reference: 1-(6-broMo-3,4-dihydro-2(1H)-isoquinolinyl)-2,2,2-trifluoro-Ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-broMo-3,4-dihydro-2(1H)-isoquinolinyl)-2,2,2-trifluoro-Ethanone(252331-63-8)
• EPA Substance Registry System: 1-(6-broMo-3,4-dihydro-2(1H)-isoquinolinyl)-2,2,2-trifluoro-Ethanone(252331-63-8)

Safety Data

• Hazardous Substances Data: 252331-63-8(Hazardous Substances Data)

Usage

General Description

1-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-2,2,2-trifluoro-ethanone is a chemical compound that contains a trifluoro-ethanone group and a 6-bromo-3,4-dihydro-2(1H)-isoquinolinyl group. It is a fluorinated organic compound that is commonly used in medicinal chemistry and drug discovery research. The presence of the bromine and isoquinolinyl groups in the molecule makes it a potential candidate for the development of pharmaceuticals with antipsychotic or antidepressant properties. Its unique structure and properties make it a valuable building block for the synthesis of novel organic compounds that could have potential therapeutic applications.

Upstream product

• 50-00-0 formaldehyd 
• 181514-21-6 N-[2-(4-bromophenyl)ethyl]-2,2,2-trifluoroacetamide 
• 215797-81-2 N-(3-bromophenethyl)-2,2,2-trifluoroacetamide 
• 226942-29-6 6-bromo-1,2,3,4-tetrahydroisoquinoline 
• 407-25-0 trifluoroacetic anhydride 
• 64-19-7 acetic acid 
• 73918-56-6 4-Bromophenethylamine 
• 58971-11-2 2-(3-bromophenyl)ethanamine 

Downstream Products

• 726136-51-2 1,2,3,4-tetrahydro-8-[2-(trifluoromethyl)phenyl]isoquinoline 
• 726136-50-1 1,2,3,4-tetrahydro-6-[2-(trifluoromethyl)phenyl]isoquinoline 
• 226942-29-6 6-bromo-1,2,3,4-tetrahydroisoquinoline 
• 75416-51-2 8-bromo-1,2,3,4-tetrahydroisoquinoline 
• 939050-65-4 6-(5-benzylbenzofuran-2-yl)-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhbiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.